Literature DB >> 31368175

Screening high-risk populations for colon and rectal cancers.

Mark A Healy1, Selvi Thirumurthi2,3, Y Nancy You1,3.   

Abstract

Currently, colorectal cancers accounted for the second-highest number of cancer deaths in the US. Hereditary syndromes, strong family history, and inflammatory bowel disease are all conditions that confer predisposition risks. In hereditary syndromes, screening must be more frequent and start earlier. With familial risk, screening should depend on the age of cancer onset and number of affected relatives. For inflammatory bowel disease, surveillance should depend on duration, severity, and extent of colitis.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  APC; adenomatous polyposis coli; colonic neoplasms; early detection; genes; hereditary nonpolyposis; rectal neoplasms; screening

Mesh:

Year:  2019        PMID: 31368175     DOI: 10.1002/jso.25648

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  4 in total

Review 1.  Extrahepatic cytochrome P450 epoxygenases: pathophysiology and clinical significance in human gastrointestinal cancers.

Authors:  Nataliya Pidkovka; Olena Rachkevych; Abbes Belkhiri
Journal:  Oncotarget       Date:  2021-02-16

Review 2.  Important roles of dietary taurine, creatine, carnosine, anserine and 4-hydroxyproline in human nutrition and health.

Authors:  Guoyao Wu
Journal:  Amino Acids       Date:  2020-02-18       Impact factor: 3.789

3.  Effect of HtrA1 Polymorphism on Sensitivity to Chemotherapy in Patients with Colon Cancer.

Authors:  Yi Yao; Nan Li
Journal:  Med Sci Monit       Date:  2020-03-27

4.  Could a Behavioral Model Explain Adherence to Second-Level Colonoscopy for Colon Cancer Screening? Results of a Cross-Sectional Study of the Palermo Province Population.

Authors:  Giuseppa Minutolo; Palmira Immordino; Alessia Dolce; Mario Valenza; Emanuele Amodio; Walter Mazzucco; Alessandra Casuccio; Vincenzo Restivo
Journal:  Int J Environ Res Public Health       Date:  2022-02-27       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.